 | Up a level |
Agarwal, Kosh; Castells, Lluís; Müllhaupt, Beat; Rosenberg, William M C; McNabb, Brian; Arterburn, Sarah; Camus, Gregory; McNally, John; Stamm, Luisa M; Brainard, Diana M; Mani Subramanian, G; Mariño, Zoe; Dufour, Jean-François; Forns, Xavier (2018). Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. Journal of hepatology, 69(3), pp. 603-607. Elsevier 10.1016/j.jhep.2018.05.039
Agarwal, Kosh; Castells, Lluis; Mullhaupt, Beat; M.C. Rosenberg, William; McNabb, Brian; Arterburn, Sarah; Camus, Gregory; McNally, John; Brainard, Diana M.; Subramanian, G. Mani; Gonsalkorala, Enoka; Londoño, Maria; Dufour, Jean-François; Forns, Xavier (October 2017). Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients (Unpublished). In: AASLD. Washington DC. October 2017.
Manns, Michael; Samuel, Didier; Gane, Edward J; Mutimer, David; McCaughan, Geoff; Buti, Maria; Prieto, Martín; Calleja, José Luis; Peck-Radosavljevic, Markus; Müllhaupt, Beat; Agarwal, Kosh; Angus, Peter; Yoshida, Eric M; Colombo, Massimo; Rizzetto, Mario; Dvory-Sobol, Hadas; Denning, Jill; Arterburn, Sarah; Pang, Phillip S; Brainard, Diana; ... (2016). Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet infectious diseases, 16(6), pp. 685-697. Elsevier 10.1016/S1473-3099(16)00052-9
